Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Personen
Suche
EN
Zurück
Poster session
PoS 1
ePoster 02
Termin
Datum:
06.12.2023
Zeit:
19:30
–
21:00
Ort / Stream:
Headache theatre
Chair
Dagny Holle-Lee
Essen, DE
Programm
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
Uwe Reuter (Berlin, DE)
ePoster
P021
Predictors of ≥50% and ≥75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
Edoardo Caronna (Barcelona, ES)
ePoster
P022
Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
Dagny Holle-Lee (Essen, DE)
ePoster
P023
Effectiveness of galcanezumab versus traditional oral migraine preventive medications: 3-month findings from the TRIUMPH observational study
Patricia Pozo-Rosich (Barcelona, ES)
ePoster
P024
Three-and-six month effectiveness of CandeSpartan in the treatment of migraine: the CandeSpartan study (NCT: 04138316)
Cristina Martinez-Badillo (Valladolid, ES)
Ángel Luis Guerrero Peral (Valladolid, ES)
David García Azorín (Valladolid, ES)
ePoster
P025
6-Month Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
Andreas Straube (Munich, DE)
ePoster
P026
Effectiveness of galcanezumab vs. traditional oral migraine preventive medications: 3-month results from Real-World TRIUMPH study for Europe [Germany, Italy, Spain, and the United Kingdom]
Saygin Gonderten (Dubai, AE)
ePoster
P027
Efficacy of rimegepant for the acute treatment of migraine in chinese and korean adults receiving concurrent preventive medication
Jo Atkinson (Tadworth, GB)
ePoster
P028
UNITE: Efficacy and impact of fremanezumab in patients with migraine and major depressive disorder
Piero Barbanti (Rome, IT)
ePoster
P029
Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
Simona Sacco (L'Aquila AQ, IT)
ePoster
P030
Rimegepant for the acute treatment of migraine in adults from China
Jo Atkinson (Tadworth, GB)
ePoster
P031
Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
Fabrizio Vernieri (Roma, IT)
ePoster
P032
Drug-resistant epicrania fugax: responding to onabotulinumtoxinA
Jorge Moral Rubio (Elche, Alicante, ES)
ePoster
P033
Long-term reductions in acute headache medication use after eptinezumab treatment in patients with prior preventive treatment failures
Anna Gryglas-Dworak (Wroclaw, PL)
ePoster
P034
Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: protocol for a randomized placebo-controlled study
Julia Jansen (Nijmegen, NL)
ePoster
P035
Efficacy and safety of fremanezumab in patients with migraine and obesity: post-hoc analysis of the phase 3 HALO-LTS and FOCUS clinical trials
Mario Ortega (West Chester, US)
ePoster
LP003
Sexuality and sexual function in females with migraine vs controls
John Rothrock (Fairfax, US)
ePoster
LP004
Migraine in the elderly: Results from the Korean population
Jin Hwangbo (Yangsan-si, KR)
ePoster
LP005
Insular cortex through AC1 pathway involved in the regulation of headache pain and negative emotions in a rat model induced by recurrent dural inflammatory soup infusion
Zhenjie Ma (Beijing, CN)
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz